BOULDER, Colo., Jan. 29, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, February 4, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies are already in progress, or are planned to begin, within the next year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520), for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and MEK162 (Novartis). For more information on Array, please go to www.arraybiopharma.com
SOURCE Array BioPharma Inc.